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Approximately two million people develop deep-vein thrombosis 
(DVT) annually, and of these an estimated 200 000 die from a fatal 
pulmonary embolism (PE).[1] Fifty percent of these cases are ‘silent’, 
and the first sign or symptom of venous thromboembolic disease 
(VTED) is a fatal PE.[2]
VTED accounts for 10% of all hospital deaths,[3] and approximately 
1 in 20 hospitalised medical patients may develop a fatal PE if they 
have not received appropriate thrombosis prophylaxis.[4]
If not fatal, untreated venous thromboembolism (VTE) may 
have serious consequences such as risk of recurrent VTE,[1] post-
thrombotic syndrome,[1] chronic thromboembolic pulmonary 
hypertension[5] and reduced quality of life.[6]
The prevalence of VTE and the use of pharmacological 
thromboprophylaxis in total hip replacement (THR), total knee 
replacement (TKR) and hip fractures have been well documented in 
published literature and in clinical trials.[1,7-10]
Although there is potentially an increased risk of VTE in foot and 
ankle surgery, the incidence of VTE is poorly understood. None of 
the available studies are comparable owing to non-uniformity of 
the patient populations, failure to distinguish between symptomatic 
and silent thrombosis, the considerable diversity in foot and ankle 
pathology, and varying aftercare protocols, which may be why the 
reported incidence of VTE after foot and ankle surgery ranges widely, 
from 0% to 36%.[11-34]
A database study in the National Health Service in the UK found 
that the rate of symptomatic VTED following ankle fracture surgery, 
total ankle replacement, hindfoot arthrodesis or first metatarsal 
surgery was <0.3% for each type of surgery.[34] Mizel et al.[21] found 
prevalences of symptomatic DVT and non-fatal PE of 0.22% and 
0.15%, respectively.
In a prospective study using colour duplex Doppler ultra-
sonography, we found a 1% incidence of DVT in 100 patients 
following hallux surgery.[35] Lapidus et al.,[36] however, found a 
28% DVT rate in patients after ankle fracture surgery who did 
not receive pharmacological prophylaxis. In two studies following 
Achilles tendon rupture repair, the incidences of DVT were 36%[19] 
and 6%.[26]
In a more recent prospective study, we found an 8.5% incidence of 
VTE in patients who required immobilisation in a below-knee cast 
and non-weightbearing for ≥4 weeks after foot and ankle surgery.[37] 
Two patients developed a PE. Neither of them had shown any clinical 
evidence of DVT.
Although the majority of recent studies do not advocate the routine 
use of chemoprophylaxis in foot and ankle surgery,[6,12,13,21,22,25,27,30,33,38-40] 
several authors recommend its use in patients with identifiable 
specific clinical risk factors.[6,8-20,26,37,41] A difficulty of long-term 
follow- up of patients is that many DVT events occur several weeks or 
longer after discharge.[37,42]
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Background. Ten percent of patients with a deep-vein thrombosis (DVT) will develop a fatal pulmonary embolism (PE), often initially 
asymptomatic. The risks and benefits of pharmacological thromboprophylaxis are well documented in respect of total joint arthroplasty 
and hip fractures, but little is understood about the incidence of venous thromboembolism (VTE) or the potential risks and benefits of 
chemoprophylaxis in foot and ankle surgery.
Objective. To determine whether prophylactic chemoprophylaxis had any impact on the prevention of VTE in a cohort of foot and ankle 
surgical patients requiring the combination of below-knee cast immobilisation and non-weightbearing for ≥4 weeks.
Methods. Between March 2014 and April 2015, a prospective cohort study of 142 patients was performed. All completed a thrombosis risk 
assessment form prior to surgery and were commenced on rivaroxaban (Xarelto) 10 mg/d postoperatively. The primary outcome measure 
was clinical VTE confirmed by compression ultrasonography (DVT) or a ventilation/perfusion scan (PE).
Results. Three patients (2.1%) developed a clinical DVT. Two did so well beyond the immobilisation and anticoagulation period, and one 
was non-compliant with therapy. The average risk factor score in this subgroup was 7. No patient had a DVT while on the prescribed 
regimen of anticoagulant therapy. Five patients (3.5%) developed wound breakdown, two requiring surgical debridement with local skin flap 
closure. One case of menorrhagia that may have been linked to the anticoagulant therapy was reported. When compared with a previous 
study, pharmacological thromboprophylaxis significantly reduced VTE risk (p=0.02).
Conclusions. Oral pharmacological thromboprophylaxis significantly reduces the risk of VTE in patients requiring cast immobilisation and 
non-weightbearing following foot and ankle surgery. The risk/benefit ratio favours this treatment as opposed to the treatment of major 
morbidity following non-fatal VTE.
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In the case of post-thrombotic syndrome, 
which may affect 20 - 50% of patients diag-
nosed with DVT, most symptoms become 
apparent within 2 years of developing 
DVT. [43] VTE is essentially a disease with 
short-term mortality and long-term mor-
bidity.
Objective
To determine whether prophylactic chemo-
prophylaxis had any impact on the prevention 
of VTE in a cohort of foot and ankle surgical 
patients requiring the combination of 
below-knee cast immobilisation and non-
weightbearing for ≥4 weeks, identified by 
us as a risk factor for VTE in a previous 
study,[37] and therefore whether its routine 
administration is justified in these selected 
patients.
The primary outcome measure was the 
development of clinical VTE, including 
infrapopliteal DVT, proximal DVT and PE. 
Proximal DVT and PE are the potentially 
fatal conditions, but infrapopliteal DVT 
may have serious consequences, as outlined 
above.
At the time of the study, two direct oral 
anticoagulants were readily available. Riva-
roxaban (Xarelto; Bayer) was chosen arbi-
trarily.
Methods
All patients aged >18 years who underwent 
foot and ankle surgery requiring the combin-
ation of below-knee immobilisation in a cast 
and non-weightbearing for ≥4  weeks were 
included in this prospective study. Patients 
who were already on anticoagulants or 
had previously had a DVT were excluded. 
During the period March 2014 - April 
2015, 142 consecutive patients who met the 
criteria were identified. No patient refused 
to participate.
After giving informed consent, every 
patient included in the study received riva-
roxaban 10 mg orally for 4 - 6 weeks, i.e. 
until he or she no longer required non-
weightbearing or cast immobilisation (which-
ever one came first). The first dose was given 
at 06h00 on the first day postoperatively, 
and the drug was administered 24-hourly 
thereafter.
Before the operation, all patients com-
pleted a thrombosis risk assessment form 
(Fig. 1), adapted from Caprini[41] and 
en dorsed by the Southern African Society 
of Thrombosis and Haemostasis. The higher 
the score, the higher is the risk of developing 
a DVT. Tourniquet time, procedure groups 
and smoking were included as possible risk 
factors. The above risk factors were identi-
fied so that the present study would be 
comparable with our previous study,[37] in 
which no patient had received any ven ous 
thromboprophylaxis postoperatively.
The primary outcome measure was the 
development of a clinically evident DVT, as 
confirmed by compression ultrasonography 
or a ventilation/perfusion lung scan in the 
case of PE.
Ethics approval was obtained from the 
Human Research Ethics Committee (Medi-
cal) of the University of the Wit watersrand, 
Johannesburg (ref. no. M131165).
Results
There were 75 male and 67 female patients, 
with a mean age of 50.9 years (range 20 - 
78). Table 1 summarises the procedure 
groups. The average body mass index (BMI) 
(kg/m2) was 29 (range 18 - 55) and the 
average risk factor score was 7 (range 3 - 15). 
Fourteen patients (9.9%) were smokers or 
had smoked within 1 year prior to surgery. 
Average tourniquet time was 86 minutes 
(range 33 - 150).
Three patients (2.1%) developed a clini-
cally evident DVT, confirmed by com-
pression ultrasonography. Two were extensive 
(proximal to the calf). One patient developed 
a clinical DVT 5 weeks after an acute Achilles 
tendon rupture repair. He admitted being 
non-compliant in taking his anticoagulation, 
which had been prescribed for 4 weeks. The 
other two patients (triple fusion and ankle 
arthrodesis) developed a DVT at 9 weeks and 
14 weeks, respectively, well after completion 
of the prophylactic anticoagulant, which had 
been prescribed for 6 weeks.
Five patients (3.5%) developed wound 
breakdown and were referred to a plastic 
surgeon. Two required major debridement 
(internal fixatives were not removed) and 
closure with a local skin flap. The remain-
ing three were treated with appropriate 
dressings.
One patient developed menorrhagia, 
which may have been related to the anti-
coagulant. The drug was stopped until the 
menorrhagia abated, and then resumed.
Two patients stopped taking their anti-
coagulant a few days after surgery because 
they suspected that there was bleeding under 
the cast. When the cast was removed no 
active bleeding was noted, and the drug was 
resumed within 2 weeks following surgery.
One of the three patients who developed 
a DVT was a smoker. The average risk factor 
score in these three patients was 7 (range 6 - 
8) v. 7.7 (range 4 - 13) in the VTE group in 
our previous study,[37] in which the average 
BMI was 34 (range 32 - 36). The average 
tourniquet time in the previous study was 
92  minutes (range 55 - 120). The numbers 
were too small for statistical analysis.
None of the above three patients developed 
a clinically evident DVT while they were 
receiving the anticoagulant.
Each risk factor represents 1 point
• Age 41 - 60 years 
• Minor surgery planned
• History of prior major surgery 
  (<1 month)
• Varicose vein (large)
• History of inammatory bowel disease
• Swollen legs (current)
• Overweight (BMI >25 kg/m2)
• Acute myocardial infarction
• Congestive heart failure (<1 month)
• Sepsis (<1 month)
• Serious lung disease including pneumonia (<1 month)
• Abnormal pulmonary function (COPD)
• Medical patient currently at bed rest
Each risk factor represents 3 points
• Age ≥75 years
• History of DVT/PE
• Family history of thrombosis
• Positive factor V Leiden
• Positive prothrombin 20210A
• Positive lupus anticoagulant
• Elevated anticardiolipin antibodies
• Other congenital or acquired thrombophilia 
  (if yes, type ____________)
Each risk factor represents 2 points
• Age 60 - 74 years
• Arthroscopic surgery
• Malignancy (present or previous)
• Major surgery (>45 minutes)
• Patient conned to bed (>72 hours)
• Immobilising plaster cast (<1 month)
• Central venous access
Each risk factor represents 5 points
• Elective major lower extremity arthroplasty
• Hip, pelvis or leg fracture (<1 month)
• Stroke with lower extremity weakness (<1 month)
• Multiple trauma (<1 month)
• Acute spinal cord injury (paralysis) 
  (<1 month)
For women only (each risk factor represents 1 point)
• Oral contraceptives or hormone replacement therapy
• Pregnancy or postpartum (<1 month)
• History of unexplained stillborn infant, recurrent spontaneous 
  abortion (≥3), premature birth with toxaemia, or 
  growth-restricted infant
TOTAL RISK FACTOR SCORE        
Total risk factor score Incidence of DVT, %  Risk level
0 - 1    <10    Low risk
2    10 - 20    Moderate risk
3 - 4    20 - 40    High risk
≥5    40 - 80    Highest risk
Fig. 1. Thrombosis risk factor assessment. (COPD = chronic obstructive pulmonary disease.)
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Discussion
Little has been written on the development and prophylaxis of VTE 
in foot and ankle surgery. Individual patient- and procedure-specific 
risk factors have been implicated in the development of VTE.[37] 
The more universally accepted risk factors have been adopted by 
Caprini[41] and are widely used worldwide.
The concern about using anticoagulation is possible adverse events. 
These have been thoroughly investigated in clinical trials using TKR, 
THR and hip fracture models, with figures of 2.9 - 6.5% for non-
major bleeding, 0.6 - 1.0% for wound-related infections, <0.1 - 4.9% 
for major bleeding, 0 - 0.4% for cerebrovascular adverse events, and 
0 - 1.4% for death from any cause.[7-10] The decision whether or not to 
use thrombosis chemoprophylaxis is therefore decided by weighing 
up the patient’s risk for bleeding against the risk of developing VTE. 
No universal guidelines are available, although the general consensus 
from various bodies[31,34,38,40] and published articles[6,12,13,21,22,24,25,27,30,33,39] 
is that use of prophylactic anticoagulation is not advocated in foot 
and ankle surgery
In a previous prospective study,[37] we found that the absolute 
number of cases of VTE after foot and ankle surgery was unacceptably 
high (11/130 (8.5%)), although this was not statistically significant 
owing to the relatively small number of cases. We identified a cohort 
of patients who were particularly prone to developing VTE after foot 
and ankle surgery. They did not have individual or procedure-specific 
risk factors per se, but were a group requiring the combination 
of cast immobilisation and non-weightbearing for a period of 
≥4  weeks. Using the χ2 test with a level of significance of p<0.05, 
the present study demonstrated that the incidence of DVT (2.1%) 
decreased significantly from 8.5%[37] (p=0.01) when prophylactic 
anticoagulation was given.
It is also important to note that one of the three patients 
who developed a DVT was non-compliant, and the other two 
developed a DVT several weeks after completion of the prophylactic 
anticoagulation.
Adverse events possibly caused by the anticoagulant were 
superficial wound sepsis (3.5%) and menorrhagia (0.7%). Procedures 
in the patients who developed superficial sepsis requiring a skin graft 
in theatre were a triple fusion, mid-tarsal fusion and non-union of the 
tibia, with an average risk factor score of 7 (range 6 - 8). There were 
no smokers in this group.
We appreciate the disadvantage of rivaroxaban as a potential 
cause of bleeding, particularly in emergency ‘second-look’ surgery. 
However, such an emergency rarely occurs in foot and ankle surgery, 
and in the infrequent case when a second-look procedure is required 
in a patient receiving rivaroxaban 10 mg/d, a waiting period of 
8 hours will suffice. If more urgent intervention is needed, a readily 
available procoagulant can be administered.
Rivaroxaban 10 mg film-coated tablets are indicated for the 
prevention of VTE in patients undergoing major orthopaedic surgery 
of the lower limbs. Although all the clinical trials have been limited 
to TKR, THR and hip fracture surgery, we considered that the same 
regimen would be adequate and safe in patients undergoing foot and 
ankle surgery where anticoagulation was indicated. Furthermore, 
the choice of using this mode of prophylaxis over the standard 
low-molecular-weight (LMW) heparin injection was the ease of 
administration and the cost factor (a 40 mg LMW heparin injection 
is approximately three times the price of 10 mg rivaroxaban as a 
once-daily dose).
Study limitations are the relatively small number of patients, the 
lack of routine postoperative duplex Doppler studies (therefore 
missing silent DVTs), and the absence of a concurrent study as 
control.
Conclusions
The current study was initiated 2 years after conclusion of the previ-
ous study by the same senior surgeons. The methodology, demo-
graphics, mode of anaesthesia and risk factors were comparable. On 
the basis of the previous study, we consider that a group of patients has 
been identified who will probably benefit from receiving prophylactic 
anticoagulation in foot and ankle surgery. We noted a significant 
decrease in the risk of developing VTE in patients requiring a 
combination of cast immobilisation and non-weightbearing status for 
a period of ≥4 weeks who received rivaroxaban.
We found that the risk/benefit ratio favours the administration 
of prophylactic anticoagulation, as the adverse events of such 
medication are relatively minor compared with life-threatening PE, 
and in the case of non-fatal VTED, the expense of treatment and 
long-term morbidity.
The ultimate decision whether or not to offer the patient venous 
thromboprophylaxis remains the prerogative of the surgeon, whose 
decision should be based on a case-by-case basis, determining the 
risk/benefit ratio for the individual patient.
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